Merus to Participate in Upcoming Investor Conferences
September 07, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Financial Results for the Second Quarter and Provides Business Update
August 05, 2021 17:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
July 21, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Participate in William Blair's Biotech Focus Conference 2021
July 07, 2021 16:20 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
June 04, 2021 12:00 ET
|
Merus N.V.
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with...
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
May 26, 2021 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 17:01 ET
|
Merus N.V.
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with...
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
May 13, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus nimmt an Kamingespräch auf der RBC Capital Markets Global Healthcare Conference 2021 teil
May 11, 2021 14:29 ET
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., USA, May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische...
Merus participera à une discussion informelle lors de la conférence sur les soins de santé de la RBC Marché des Capitaux 2021
May 11, 2021 14:29 ET
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 11 mai 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d'oncologie de stade clinique qui développe des anticorps multispécifiques...